Ursodeoxycholic Acid alleviates bleomycin-induced pulmonary fibrosis by inhibiting the STING-BIP signaling pathway

Lung fibrosis is a condition where the delicate, spongy tissue of the lungs becomes thick and stiff, much like a scar forming on skin that never quite heals. This scarring makes it difficult for oxygen to pass into the blood, slowly robbing the body of its breath. While doctors have a few medicines that can slow this process down, they cannot reverse the damage or restore the lung's original function. One of the most common ways researchers study this disease is by using a drug called bleomycin, which is effective at killing cancer cells but unfortunately causes severe lung scarring as a side effect. This side effect creates a perfect, if tragic, model for scientists to observe how lung tissue turns into scar tissue and to test new ways to stop it. For decades, the focus has been on managing the symptoms, but a growing body of research suggests that the root of the problem lies in a complex chain reaction inside our cells, involving inflammation and a specific type of cellular stress that triggers the body to lay down too much scar material.

In a recent study, researchers set out to see if a substance called ursodeoxycholic acid, or UDCA, could stop this chain reaction. UDCA is a natural compound found in bear bile, a substance that has been used in traditional medicine for thousands of years to treat liver and eye problems. While it is already approved by regulators to treat certain liver conditions, its potential to heal the lungs has remained largely unexplored. The team, working with both living mice and human lung cells in a lab, wanted to know if UDCA could protect the lungs from the severe damage caused by bleomycin. They were particularly interested in a specific pathway inside the cell—a communication line involving two proteins known as STING and BIP—that acts like a switch to turn on inflammation and stress responses. If they could find a way to turn that switch off, they reasoned, they might be able to prevent the lungs from turning into scar tissue.

The researchers began by creating a model of lung injury in mice. They administered a dose of bleomycin directly into the windpipes of the animals, which reliably caused the lungs to swell with fluid and begin the process of scarring. After a week, they started treating some of these mice with UDCA, giving them the substance daily for three weeks. The results were striking. The mice that received UDCA maintained their body weight much better than the untreated mice, who had lost significant mass due to the illness. When the researchers examined the lungs, they found that the treated animals had far less fluid buildup and far fewer signs of the chaotic inflammation that usually accompanies lung injury. The lung tissue itself looked much healthier, with the thick, stiff walls of the air sacs remaining thin and flexible, similar to the healthy lungs of mice that had never been exposed to the damaging drug.

To understand exactly what was happening inside the tissue, the scientists looked at the chemical makeup of the lungs. In a healthy lung, the structure is built from a specific type of protein network. In fibrosis, this network becomes overloaded with collagen, a tough fiber that creates the scar. The study showed that the mice treated with UDCA had significantly lower levels of this excess collagen. They also found that the treated mice had lower levels of a protein called alpha-SMA, which is a marker for the cells that actively build scars, and higher levels of E-cadherin, a protein that helps keep lung cells healthy and connected. Essentially, UDCA seemed to stop the lung cells from transforming into the aggressive, scar-building cells that drive the disease forward.

The team then turned their attention to the immune system. Inflammation is the body's alarm system, but in fibrosis, it stays switched on for too long, causing damage. The researchers measured the levels of inflammatory signals in the blood and lung fluid of the mice. They found that the mice treated with UDCA had much lower levels of these signals, including substances like TNF-alpha and IL-6, which are known to recruit more immune cells to the site of injury and worsen the damage. This suggested that UDCA was calming the immune system's overreaction, giving the lung tissue a chance to recover rather than being constantly under attack.

To confirm that these effects were happening at the cellular level and not just in the whole animal, the researchers moved to a petri dish. They used human lung cells, which they activated with a growth factor called TGF-beta1 to mimic the conditions of fibrosis. When these cells were exposed to UDCA, they stopped multiplying as rapidly and stopped moving around as much, behaviors that are typical of cells that are about to form scar tissue. Just as in the mice, the treated cells produced less of the scar-building proteins and more of the healthy cell markers. This confirmed that UDCA was acting directly on the lung cells to change their behavior.

The most critical part of the study was uncovering how UDCA achieved this. The researchers suspected that the drug was interfering with the STING-BIP signaling pathway, a specific mechanism inside the cell that senses stress and triggers inflammation. Using a computer model, they first showed that the UDCA molecule could physically fit into the STING protein, like a key fitting into a lock, which would prevent it from working. They then tested this in the lab. In the mice and the cells that were damaged by the fibrosis-inducing agents, the levels of STING and BIP proteins were very high. However, in the samples treated with UDCA, the levels of these proteins dropped significantly. This provided strong evidence that UDCA was indeed blocking this specific pathway. By stopping the STING-BIP signal, the drug prevented the cell from launching the inflammatory and stress responses that lead to scarring.

The study concludes that ursodeoxycholic acid offers a promising new way to treat lung fibrosis. It does not just mask the symptoms; it appears to intervene in the biological process that causes the lungs to scar. By blocking the STING-BIP pathway, UDCA reduces inflammation, stops the overproduction of scar tissue, and helps preserve the healthy structure of the lung. While this research was conducted in animals and cells, and more work is needed before it can be used as a standard treatment for people, the findings provide a clear and detailed map of how a known, safe substance might be repurposed to fight a difficult and often fatal disease. The work suggests that by targeting the specific switches inside our cells that trigger scarring, we may be able to keep our lungs breathing freely for longer.